New technology for long-lasting naloxone to treat opioid overdose
Novel formulation technology for the sustained release naloxone to improve outcomes in the management of opioid overdose
This study is testing a new way to deliver naloxone, a medication that helps people who have overdosed on opioids, by using a special gel that slowly releases the medicine over time, making it easier for those with opioid use disorder to get the help they need without needing multiple doses.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lynthera Corporation NIH-funded |
| Lab location | 1 site (Lancaster, United States) |
| Project ID | NIH-10786306 on NIH RePORTER |
What this research studies
This research focuses on developing a new formulation of naloxone that can be released slowly over time to improve its effectiveness in treating opioid overdoses. The approach involves creating a special hydrogel that contains naloxone-encapsulated nanoparticles, which will be injected under the skin and turn into a gel at body temperature. This method aims to provide a more sustained release of naloxone, potentially reducing the need for repeated doses and minimizing withdrawal symptoms in patients with opioid use disorder.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of opioid overdose, including those with opioid use disorder.
Not a fit: Patients who do not use opioids or are not at risk of overdose may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the number of opioid overdose deaths by providing a more effective treatment option.
How similar studies have performed: While naloxone is already a well-established treatment for opioid overdose, this specific formulation approach is novel and has not been extensively tested.
Where this research is happening
Lancaster, United States
- Lynthera Corporation — Lancaster, United States (Active)
Researchers
- Principal investigator: Torres Luna, Cesar — Lynthera Corporation
- Study coordinator: Torres Luna, Cesar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.